A Study of Viracept in HIV-Positive Women
Launched by AGOURON PHARMACEUTICALS · Aug 30, 2001
Trial Information
Current as of July 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV infection.
- • CD4 T cell count \<= 400 cells/mm3.
- • Exclusion Criteria
- Prior Medication:
- Excluded:
- • Prior therapy or less than 1 month of therapy with d4T and/or 3TC.
- • Prior protease inhibitor therapy.
About Agouron Pharmaceuticals
Agouron Pharmaceuticals is a biopharmaceutical company dedicated to advancing innovative therapies for the treatment of serious medical conditions. With a strong focus on research and development, Agouron leverages cutting-edge science and technology to discover and optimize novel drug candidates. The company is committed to improving patient outcomes through rigorous clinical trials and collaborations with healthcare professionals. By prioritizing safety and efficacy, Agouron aims to deliver transformative solutions that address unmet medical needs and enhance the quality of life for patients around the world.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Los Angeles, California, United States
Houston, Texas, United States
New Orleans, Louisiana, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials